OncoMatch

OncoMatch/Clinical Trials/NCT06190886

A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

Is NCT06190886 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies PTX-912 for advanced cancer.

Phase 1RecruitingProviva Therapeutics, Inc.NCT06190886Data as of May 2026

Treatment: PTX-912The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

Adequate bone marrow and organ function, defined by the following laboratory results obtained within 14 days before first dose of study drug.

Kidney function

Adequate bone marrow and organ function, defined by the following laboratory results obtained within 14 days before first dose of study drug.

Liver function

Adequate bone marrow and organ function, defined by the following laboratory results obtained within 14 days before first dose of study drug.

Cardiac function

Impaired cardiovascular function or clinically significant cardiovascular disease [excluded]

Adequate bone marrow and organ function, defined by the following laboratory results obtained within 14 days before first dose of study drug. Impaired cardiovascular function or clinically significant cardiovascular disease [excluded].

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope National Medical Center · Duarte, California
  • University of Miami · Miami, Florida
  • Nebraska Cancer Specialists (NCS) · Omaha, Nebraska

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify